As the political winds shift on a whim and public distrust of the pharma industry reaches fever pitch over drug pricing, ...

If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 ...

Generate:Biomedicines’ Nicole Clouse is one of the key legal minds trying to understand who owns what AI creates. The answers ...

The MIT professor of management, who already sits on the CDC's revamped immunization advisory committee, is a known skeptic ...

The White House has denied reports that the government could soon ban COVID-19 vaccines, noting that in the absence of an ...

While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...

Based on new data, argenx expects to file for the expansion of Vyvgart’s label into patients with generalized myasthenia ...

Appia Bio's shutdown continues an unfortunate trend this year that has seen biotech closures nearly every month.

Closely watched data from Eli Lilly and Viking Therapeutics this month have reignited the discussion around oral weight-loss ...

The biotech sector has not seen an IPO in six months. The market has remained frozen amid broader macro pressures and the ...

Companies have claimed improvements to yield, batch consistency and output while acknowledging the risks and challenges ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...